HANGZHOU, China, June 22, 2022 /PRNewswire/ VenusP-Valve, an in-house developed novel medical device of Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as "Venus Medtech")
HANGZHOU, China, June 22, 2022 /PRNewswire/ VenusP-Valve, an in-house developed novel medical device of Venus Medtech (Hangzhou) Inc. (2500.HK, hereinafter referred to as "Venus Medtech"), recently completed its first compassionate use at University of Virginia Advanced Cardiac Valve Center in the U.S. The procedure was performed at the Center by Professor Scott Lim's team under on-site guidance from Professor Yuan Feng and remote guidance from Professor Mao Chen, who are both from Cardiology Department, West China Hospital, Sichuan University in China. As the first-ever clinical application of a Chinese-developed heart valve product in the U.S., the case corroborates not only the unique clinical value of VenusP-Valvebut also the significance of global-oriented innovation. Although there are several transcatheter pulmonic valve replacement (TPVR) products available in the U.S. market, such as Melody TPV and Harmony TPV by Medtronic and the SAPIEN series by Edwards, they